This observational, multi-center study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in renal anemia correction in dialysed patients in daily clinical practice. Patient will receive Mircera according to local summary of product characteristics. Data will be collected for 12 months.

Inclusion Criteria:

• Adult patients, >/=18 years of age
• Adequate iron status
• Signed informed consent form

Exclusion Criteria:

• Anemia due to non-renal causes
• Where investigator considers the patient unsuitable for inclusing for other reasons (e.g. severe co-morbidities as active bleeding, infections or cancer)
• Pregnant or lactating female patients
• Any contraindications against treatment with Mircera (according to local Summary of Product Characteristics)

Patients with renal anemia and on dialysis therapy